Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp lessened its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 19.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 89,534 shares of the company’s stock after selling 21,735 shares during the quarter. Bank of New York Mellon Corp’s holdings in Takeda Pharmaceutical were worth $1,159,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Raymond James & Associates boosted its position in Takeda Pharmaceutical by 5.3% in the 2nd quarter. Raymond James & Associates now owns 255,762 shares of the company’s stock worth $3,310,000 after purchasing an additional 12,862 shares in the last quarter. Blue Trust Inc. boosted its holdings in Takeda Pharmaceutical by 74.0% during the second quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock worth $76,000 after buying an additional 2,330 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its position in Takeda Pharmaceutical by 15.9% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 29,870 shares of the company’s stock valued at $387,000 after buying an additional 4,107 shares during the period. Tsfg LLC increased its holdings in Takeda Pharmaceutical by 8.3% in the second quarter. Tsfg LLC now owns 25,639 shares of the company’s stock valued at $332,000 after buying an additional 1,965 shares in the last quarter. Finally, OLD National Bancorp IN raised its position in shares of Takeda Pharmaceutical by 7.9% in the second quarter. OLD National Bancorp IN now owns 31,261 shares of the company’s stock worth $405,000 after acquiring an additional 2,297 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

NYSE:TAK opened at $14.80 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.26 and a debt-to-equity ratio of 0.65. Takeda Pharmaceutical Company Limited has a 52 week low of $12.57 and a 52 week high of $16.06. The stock’s 50-day moving average price is $14.32 and its 200-day moving average price is $13.76. The stock has a market capitalization of $47.09 billion, a PE ratio of 26.91, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.37 by $0.19. The company had revenue of $7.75 billion for the quarter. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. As a group, equities analysts expect that Takeda Pharmaceutical Company Limited will post 1.63 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.